Tirzepatide for weight loss in people with atrial fibrillation
Treatments studied
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the heart rhythm condition atrial fibrillation. If you have AFib and are overweight or obese, this trial may be an option for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- Your body mass index (BMI) is between 27 and 60.
- You have been diagnosed with atrial fibrillation that causes symptoms, and it is either occasional (paroxysmal) or persistent.
- You are not currently taking any GLP-1 or similar weight-loss medications, and have not used them in the last 6 months.
- You are able and willing to inject the medication yourself.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a weight-loss medication called tirzepatide (given as a shot) helps prevent atrial fibrillation from coming back after a catheter ablation procedure. It is for people who have both obesity and atrial fibrillation, and it may help improve heart health by reducing weight and inflammation.
This study tests whether tirzepatide (a weekly injection for weight loss and diabetes) can prevent atrial fibrillation from coming back after catheter ablation, in people with obesity and heart failure with preserved ejection fraction. It may help by reducing weight and improving heart function.
This study tests a medicine called tirzepatide to see if it helps people with overweight or obesity lose weight, whether or not they also have type 2 diabetes. Tirzepatide is given as an injection and works on hormones that control appetite.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests if tirzepatide is more effective than standard obesity treatments for adults who have a BMI between 30 and 35 and one weight-related health condition, but do not have diabetes. The goal is to help you lose weight.
This study tests a medication called tirzepatide for people with type 1 diabetes who also have overweight or obesity. Tirzepatide may help with weight loss and blood sugar control, and you'll use a continuous glucose monitor throughout the study.
Hear when a new Atrial fibrillation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.